AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (20% carbohydrate, 60% fat)
Number of subjects: 164
Study 29233719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum feeding phase following the test phase
Number of subjects: 164
Study 26813359 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated human recombinant hyaluronidase (PEGPH20) at doses of 1.0 μg/kg (n = 4), 1.6 μg/kg (n = 4), or 3.0 μg/kg (n = 20) in combination with gemcitabine (Gem)
Number of subjects: 28
Study 26813359 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 in combination with Gem for patients with high hyaluronan (HA) levels
Number of subjects: 28
Study 26813359 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 in combination with Gem for patients with low hyaluronan (HA) levels
Number of subjects: 28
Study 22723960 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HR (isoniazid plus rifampicin for 4 months)
Number of subjects: 0
Study 22723960 — intervention group
Group type: COMPARATOR
Intervention: 6HE (isoniazid plus ethambutol for 6 months)
Number of subjects: 0
Study 20147575 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 21
Study 18541041 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST)
Number of subjects: 109
Study 18541041 — intervention group
Group type: COMPARATOR
Intervention: Low-strength static magnets (LSSM)
Number of subjects: 109
Study 15747273 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-PEEP
Number of subjects: 25
Study 15747273 — intervention group
Group type: COMPARATOR
Intervention: PCV-ZEEP
Number of subjects: 25
Study 15747273 — intervention group
Group type: COMPARATOR
Intervention: VCV-ZEEP
Number of subjects: 25
Study 12220774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 352
Study 12220774 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 352
Study 9825371 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. propafenone (PFN) (2 mg/kg bolus followed by 0.0078 mg/kg/min infusion)
Number of subjects: 123
Study 9825371 — intervention group
Group type: EXPERIMENTAL
Intervention: o.s. propafenone (PFN) (600 mg)
Number of subjects: 123
Study 9825371 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLA)
Number of subjects: 123
Study 8024919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 30
Study 8024919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2681717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin
Number of subjects: 75
Study 2681717 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 75
Study 2681717 — intervention group
Group type: COMPARATOR
Intervention: No heparin (anti-embolism stockings)
Number of subjects: 75
Study 1090708 — intervention group
Group type: EXPERIMENTAL
Intervention: Major tranquilizer (neuroleptic) treatment
Number of subjects: 0
Study 1090708 — intervention group
Group type: COMPARATOR
Intervention: Therapy resistant schizophrenic patients
Number of subjects: 0
Study 29363217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 15 mg
Number of subjects: 149
Study 29363217 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 149
Study 29363217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 149
Study 29363217 — intervention group
Group type: COMPARATOR
Intervention: Active placebo tolterodine 1 mg
Number of subjects: 149
Study 27509214 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF socket filling
Number of subjects: 22
Study 27509214 — intervention group
Group type: COMPARATOR
Intervention: Natural healing (Control)
Number of subjects: 22
Study 25362008 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/5 mL elemental zinc as zinc sulfate) for 2 weeks
Number of subjects: 272
Study 25362008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (syrup base) for 2 weeks
Number of subjects: 272
Study 22674156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol (1 mg loading dose followed by 0.2 mg/h infusion)
Number of subjects: 91
Study 22674156 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (infusion of the same volume)
Number of subjects: 91
Study 22674156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol
Number of subjects: 91
Study 22674156 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 91
Study 20299607 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d
Number of subjects: 226
Study 20299607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 18064534 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune thyroid disease (ATD)
Number of subjects: 101
Study 18064534 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 101
Study 15921927 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone calls to black churches
Number of subjects: 79
Study 15921927 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone calls to white churches
Number of subjects: 79
Study 15921927 — intervention group
Group type: COMPARATOR
Intervention: Control group for black churches
Number of subjects: 79
Study 15921927 — intervention group
Group type: COMPARATOR
Intervention: Control group for white churches
Number of subjects: 79
Study 12675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (0.015 mg/kg) followed by repeat dose (0.08 mg/kg) at peak D1 suppression
Number of subjects: 22
Study 12675179 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium bromide (0.08 mg/kg) at peak DBS ratio suppression
Number of subjects: 22
Study 10326708 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity training (30 minutes daily biking on an ergometer in supine position)
Number of subjects: 59
Study 10326708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 59
Study 7843434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 42
Study 7843434 — intervention group
Group type: COMPARATOR
Intervention: Cervical cap insemination
Number of subjects: 42
Study 2636408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 35
Study 2636408 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen and beclomethason diproprionate
Number of subjects: 35
Study 366454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilorone hydrochloride, 1 gm per week
Number of subjects: 16
Study 366454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7064013 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 20
Study 7064013 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2
Number of subjects: 20
Study 31960395 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet education program
Number of subjects: 84
Study 31960395 — intervention group
Group type: COMPARATOR
Intervention: Control group (guidance for swallowing exercise only)
Number of subjects: 84
Study 30844848 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular allergy diagnostics (MAD)
Number of subjects: 0
Study 30844848 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory allergy diagnostics
Number of subjects: 0
Study 30844848 — intervention group
Group type: COMPARATOR
Intervention: Allergen immunotherapy
Number of subjects: 0
Study 30111722 — intervention group
Group type: EXPERIMENTAL
Intervention: BLISS (Baby-Led Weaning, modified)
Number of subjects: 206
Study 30111722 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study 27899400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (titrated up to a maximum of 100 mg daily over 28 days)
Number of subjects: 240
Study 27899400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25099071 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt drink with added plant stanol esters (4 g)
Number of subjects: 40
Study 25099071 — intervention group
Group type: COMPARATOR
Intervention: Regular yogurt drink (Control)
Number of subjects: 40
Study 20881023 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 5
Study 19447438 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser ablation of the prostate
Number of subjects: 109
Study 19447438 — intervention group
Group type: COMPARATOR
Intervention: Photoselective vaporization of the prostate
Number of subjects: 109
Study 17880352 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step involvement
Number of subjects: 733
Study 17880352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality measures (Religious Background and Behaviors scale and spiritual awakening item)
Number of subjects: 733
Study 15083783 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cm surgical excision margin
Number of subjects: 426
Study 15083783 — intervention group
Group type: COMPARATOR
Intervention: 1-cm surgical excision margin
Number of subjects: 426
Study 12516995 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 351
Study 12516995 — intervention group
Group type: COMPARATOR
Intervention: Control (Hepatitis B vaccine)
Number of subjects: 351
Study 9658375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine (3 injections at 0, 1, and 6 months)
Number of subjects: 242
Study 9658375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine
Number of subjects: 242
Study 8017413 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg immediate-release lithium carbonate tablets (Lithotab)
Number of subjects: 12
Study 8017413 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg extended-release lithium carbonate tablets (Eskalith CR)
Number of subjects: 12
Study 8017413 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg extended-release lithium carbonate tablets (Lithobid)
Number of subjects: 12
Study 8017413 — intervention group
Group type: COMPARATOR
Intervention: All three products
Number of subjects: 12
Study 2688618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 10
Study 2688618 — intervention group
Group type: COMPARATOR
Intervention: Contralateral eye (control)
Number of subjects: 10
Study 162924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (3 mg/kg every 24 hr for up to 7 days)
Number of subjects: 20
Study 162924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 162924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Number of subjects: 20
Study 31562018 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-generated wall structure
Number of subjects: 10
Study 31562018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-generated wall structure
Number of subjects: 10
Study 31397727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counselling with trained disclosure counsellors and culturally tailored materials
Number of subjects: 285
Study 31397727 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study 27913092 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 8
Study 27913092 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 8
Study 26698241 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF operation group
Number of subjects: 66
Study 26698241 — intervention group
Group type: COMPARATOR
Intervention: Wallis operation group
Number of subjects: 66
Study 23411886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Number of subjects: 224
Study 21195296 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 14
Study 21195296 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 14
Study 19446144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch applied to the trigger point for 4 days (total daily dose, 350 mg)
Number of subjects: 60
Study 19446144 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration of the trigger point with two 1-mL injections of 0.5% bupivacaine hydrochloride given 2 days apart
Number of subjects: 60
Study 19446144 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch applied to the trigger point for 4 days
Number of subjects: 60
Study 17308963 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (Clivarin) 3,436 IU anti-Xa/0.6 ml, self-administered twice daily for 8 weeks
Number of subjects: 29
Study 17308963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15111849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron patch (Hemashield Finesse) closure
Number of subjects: 273
Study 15111849 — intervention group
Group type: COMPARATOR
Intervention: Vein closure
Number of subjects: 273
Study 10389549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 micrograms
Number of subjects: 239
Study 10389549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 8779367 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.0 MAC
Number of subjects: 60
Study 8779367 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (2:1) anaesthesia supplemented with fentanyl
Number of subjects: 60
Study 8779367 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.25 MAC
Number of subjects: 60
Study 8779367 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5 MAC
Number of subjects: 60
Study 1739321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual speech therapy
Number of subjects: 42
Study 1739321 — intervention group
Group type: COMPARATOR
Intervention: Weekly speech therapy
Number of subjects: 42
Study 6473024 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 48
Study 6473024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery instructions
Number of subjects: 48
Study 6473024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30856542 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Dulce diabetes care management (PD)
Number of subjects: 0
Study 30856542 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Dulce with technology enhancement (PD-TE)
Number of subjects: 0
Study 30856542 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 30142818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 146
Study 30142818 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture
Number of subjects: 146
Study 30142818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 27514456 — intervention group
Group type: EXPERIMENTAL
Intervention: New suturing technique
Number of subjects: 128
Study 27514456 — intervention group
Group type: COMPARATOR
Intervention: Traditional suturing technique
Number of subjects: 128
Study 23708466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50 or 70 mg
Number of subjects: 317
Study 23708466 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 317
Study 23708466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 23362296 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 311
Study 23362296 — intervention group
Group type: COMPARATOR
Intervention: 3TC/ABC
Number of subjects: 311
Study 20844049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) therapy
Number of subjects: 0
Study 18164043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restraint (measured using the Three-Factor Eating Questionnaire)
Number of subjects: 24
Study 15671215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (12 g/d for 3 wk)
Number of subjects: 16
Study 15671215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12509647 — intervention group
Group type: EXPERIMENTAL
Intervention: Zincum gluconicum nasal gel (33 mmol/l), administered four times daily until symptoms resolved, for a maximum of 10 days.
Number of subjects: 80
Study 12509647 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal gel, administered four times daily until symptoms resolved, for a maximum of 10 days.
Number of subjects: 80
Study 12509647 — intervention group
Group type: EXPERIMENTAL
Intervention: Zincum gluconicum nasal gel
Number of subjects: 80
Study 12509647 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal gel
Number of subjects: 80
Study 10933617 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine
Number of subjects: 92
Study 10933617 — intervention group
Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 92
Study 9016421 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement therapy
Number of subjects: 37
Study 9016421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1642912 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia (TIVA: propofol and alfentanil)
Number of subjects: 50
Study 1642912 — intervention group
Group type: COMPARATOR
Intervention: Inhalation technique (propofol and alfentanil followed by nitrous oxide and isoflurane)
Number of subjects: 50
Study 6443759 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg for the first 2 days, then 20 mg daily)
Number of subjects: 1282
Study 6443759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1282
Study 6443759 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1282
Study 6443759 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam and Placebo
Number of subjects: 1282
Study 30266267 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 80
Study 30266267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29878617 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections (n=45)
Number of subjects: 89
Study 29878617 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injections (n=44)
Number of subjects: 89
Study 25252255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Number of subjects: 20
Study 25252255 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Number of subjects: 20
Study 25252255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed in-office bleaching technique.
Number of subjects: 20
Study 25252255 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-office bleaching technique.
Number of subjects: 20
Study 23249399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducational program (12 weekly sessions of 1.5 hours each led by two nurses)
Number of subjects: 246
Study 23249399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 246
Study 20675669 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (ETG)
Number of subjects: 40
Study 20675669 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (ICG)
Number of subjects: 40
Study 18394266 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin zeta
Number of subjects: 609
Study 18394266 — intervention group
Group type: COMPARATOR
Intervention: epoetin alpha
Number of subjects: 609
Study 16110722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap method for cost-effectiveness analysis
Number of subjects: 0
Study 16110722 — intervention group
Group type: EXPERIMENTAL
Intervention: Resampling individuals and clusters
Number of subjects: 0
Study 14583178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor (ARI); administration details not specified
Number of subjects: 0
Study 14583178 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetic patients and control rats)
Number of subjects: 0
Study 14583178 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic rats
Number of subjects: 0
Study 9987171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (5, 10, 20, and 40 micrograms/ml)
Number of subjects: 0
Study 9987171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (5 micrograms/ml)
Number of subjects: 0
Study 9987171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepagene vaccine (10 micrograms/ml or more)
Number of subjects: 0
Study 9987171 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated 'S' containing vaccines
Number of subjects: 0
Study 8341891 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methamphetamine (40-60 mg)
Number of subjects: 16
Study 8341891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8341891 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methamphetamine (20 mg)
Number of subjects: 16
Study 8341891 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 or 10 mg methamphetamine)
Number of subjects: 16
Study 3521691 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg orally with naloxone intravenously
Number of subjects: 6
Study 3521691 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg orally with 0.9% saline vehicle (placebo) intravenously
Number of subjects: 6
Study 29472258 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Learning Environments for Compassionate Care (CLECC) intervention
Number of subjects: 627
Study 29472258 — intervention group
Group type: COMPARATOR
Intervention: Control (No educational activity)
Number of subjects: 627
Study 29472258 — intervention group
Group type: COMPARATOR
Intervention: Nursing empathy (measured by Jefferson Scale of Empathy)
Number of subjects: 627
Study 27605230 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (COX-2 inhibitor) for 4 weeks postoperatively
Number of subjects: 23